Funding comes after the company meets key milestones with new collaborations and studies, product enhancements, and reimbursement progress.
September 22, 2020
We recently conducted a cost savings analysis for healthcare organizations interested in bringing liquid biopsy testing in-house. We discovered that, compared to outsourcing, in-house liquid biopsy testing with an actionable circulating tumor DNA (ctDNA) panel would enable healthcare organizations to attain substantial cost savings -- $2.7M per 1,000 cancer patients.
August 27, 2020
DeciBio interviewed Canexia Health's Brady Davis to discuss how Canexia Health and Project ACTT (Access to Testing and Treatment) are leveraging Canexia’s tech transfer platform and liquid biopsy test, Follow IT, to bridge the gap between the Canadian cancer community and molecular testing during the COVID-19 pandemic.
August 7, 2020
British Columbia-based Digital Technology Supercluster has announced a cumulative investment of approximately $30 million into 17 projects, including Project ACTT led by Canexia Health, through its COVID-19 program, launched in April to contribute to Canada’s Plan to Mobilize Industry to fight the pandemic.
July 22, 2020
Canadian firm Canexia Health is hoping that its leadership of a countrywide effort to widen patient access to liquid biopsy testing during the COVID-19 pandemic.
July 16, 2020
A consortium led by Vancouver’s Canexia Health (formerly Contextual Genomics) will soon offer critical testing and treatment options for Canadian cancer patients during the COVID-19 pandemic.
July 16, 2020
In response to restricted access to critical diagnostics for cancer patients resulting from the COVID-19 pandemic, a Canadian consortium led by Canexia Health (formerly named Contextual Genomics) has launched Project ACTT (Access to Cancer Testing & Treatment).
July 15, 2020
A consortium led by Vancouver-based Canexia Health (formerly Contextual Genomics) will enable access to critical testing and treatment options for Canadian cancer patients during the COVID-19 pandemic.
July 15, 2020
Early this morning we announced an initiative to deliver and enhance a minimally invasive circulating tumor DNA (ctDNA) test to cancer patients across Canada in response to COVID-19.
June 15, 2020
In the last decade many new targeted therapies have been approved by the FDA.
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.